The Breakthrough Prize Foundation awarded Life Sciences prizes to pioneering teams behind landmark gene therapies, including work connected to a US-available retinal blindness treatment and efforts that linked gene discovery to beta thalassemia and sickle cell outcomes. The reporting credits Jean Bennett, retinal surgeon Albert Maguire, and Katherine High for their contributions to retinal gene therapy, and highlights Swee Lay Thein and Stuart Orkin’s path from identifying genetic drivers of fetal hemoglobin to clinical translation. The awards add to momentum for gene therapy as an increasingly institutionalized platform area, with continued emphasis on durability, delivery approaches, and translational pathway design.